Coresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 11, 1998, Pages 3038-3043

  Tachedjian, Gilda ^a,b   French, Martyn ^c   Mills, John ^a  

^a MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^b New York Presbyterian Columbia University Medical Center   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

FOSCARNET; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

ARTICLE; GENE SEQUENCE; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR EVOLUTION; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STRAIN DIFFERENCE; VIRUS DETECTION; VIRUS MUTATION; VIRUS RESISTANCE;

EID: 0031784652     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.11.3038     Document Type: Article

References (33)

1. Bhattacharyya, G. K., and R. A. Johnson. 1977. Statistical concepts and methods. John Wiley and Sons, New York, N.Y.
2. Erlich, K. S., M. A. Jacobson, J. E. Koehler, S. E. Follansbee, D. P. Drennan, L. Gooze, S. Safrin, and J. Mills. 1989. Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial. Ann. Intern. Med. 110:7111-713.
3. Fitzgibbon, J. E., R. M. Howell, C. A. Haberzettl, S. J. Sperber, D. J. Gocke, and D. T. Dubin. 1992. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob. Agents Chemother. 36:153-157.
4. Fletcher, C. V., A. C. Collier, F. S. Rhame, D. Bennett, M. F. Para, C. C. Beatty, C. E. Jones, and H. H. Balfour, Jr. 1994. Foscarnet for suppression of human immunodeficiency virus replication. Antimicrob. Agents Chemother. 38:604-607.
5. Glesby, M. J., D. R. Hoover, S. Weng, N. M. Graham, J. P. Phair, R. Detels, M. Ho, and A. J. Saab. 1996. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. J. Infect. Dis. 173:1477-1480.
6. Harada, S., Y. Koyanagi, and N. Yamamoto. 1985. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 229:563-566.
7. Harrigan, P. R., I. Kinghorn, S. Bloor, S. D. Kemp, I. Najera, A. Kohli, and B. A. Larder. 1996. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J. Virol. 70:5930-5934.
8. Ho, D. D., T. Toyoshima, H. Mo, D. J. Kempf, D. Norbeck, C. M. Chen, N. E. Wideburg, S. K. Burt, J. W. Erickson, and M. K. Singh. 1994. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J. Virol. 68:2016-2020.
9. Hooker, D. J., G. Tachedjian, A. E. Solomon, A. D. Gurusinghe, S. Land, C. Birch, J. L. Anderson, B. M. Roy, E. Arnold, and N. J. Deacon. 1996. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3′-azido-3′-deoxytnymidine. J. Virol. 70:8010-8018.
10. Iverson, A. K., R. W. Shafer, K. Wehrly, M. A. Winters, J. I. Mullins, B. Chesebro, and T. C. Merigan. 1996. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol. 70:1086-1090.
11. Kellam, P., C. A. Boucher, and B. A. Larder. 1992. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci. USA 89:1934-1938.
12. Kellam, P., and B. A. Larder. 1994. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 38:23-30.
13. Kleim, J. P., R. Bender, R. Kirsch, C. Meichsner, A. Paessens, and G. Riess. 1994. Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase. Virology 200:696-701.
14. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
15. Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
16. Larder, B. A., G. Darby, and D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
17. McGavin, C. H., S. A. Land, K. L. Sebire, D. J. Hooker, A. D. Gurusinghe, and C. J. Birch. 1996. Syncytium-inducing phenotype and zidovudine susceptibility of HIV-1 isolated from post-mortem tissue. AIDS 10:47-53.
18. Medveczky, M. M., E. Horvath, T. Lund, and P. G. Medveczky. 1997. In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus. AIDS 11:1327-1332.
19. Mellors, J. W., H. Z. Bazmi, R. F. Schinazi, B. M. Roy, Y. Hsiou, E. Arnold, J. Weir, and D. L. Mayers. 1995. Novel mutations in the reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Antimicrob. Agents Chemother. 39:1087-1092.
20. Mocroft, A., M. Youle, B. Gazzard, J. Morcinek, R. Halai, A. N. Phillips, and the Royal Free/Chelsea and Westminster Hospitals Collaborative Group. 1996. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. AIDS 10:1101-1105.
21. Myers, G., B. Korber, S. Wain-Hobson, R. F. Smith, and G. N. Pavlakis. 1993. Human retroviruses and AIDS: a compilation and analysis of nucleic acid and amino acid sequences. Theoretical Biology and Biophysics Group T-10, Los Alamos National Laboratory, Los Alamos, N.M.
22. Nijhuis, M., R. Schuurman, D. de Jong, R. van Leeuwen, J. Lange, S. Danner, W. Keulen, T. de Groot, and C. A. Boucher. 1997. Lamivudine-resistant human immunodeficiency virus type I variants, (184V) require multiple amino acid changes to become co-resistant to zidovidine in vivo. J. Infect. Dis. 176:398-405.
23. Richman, D. D., D. Havlir, J. Corbeil, D. Looney, C. Ignacio, S. A. Spector, J. Sullivan, S. Cheeseman, K. Barringer, D. Pauletti, C.-K. Shih, M. Myers, and J. Griffin. 1994. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1660-1660.
24. Rocancourt, D. C. Bonnerot, H. Jouin, M. Emerman, and J. F. Nicolas. 1990. Activation of a β-galactosidase recombinant provirus: application to titration of human immunodeficiency virus (HIV) and HIV-infected cells. J. Virol. 64:2660-2668.
25. Safrin, S., T. G. Berger, I. Gilson, P. R. Wolfe, C. B. Wofsy, J. Mills, and K. K. Biron. 1991. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann. Intern. Med. 115:19-21.
26. Safrin, S., C. Crumpacker, P. Chatis, R. Davis, R. Hafner, J. Rush, H. A. Kessler, B. Landry, and J. Mills. 1991. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N. Engl. J. Med. 325:551-555.
27. Sandstrom, E. G., R. E. Byington, J. C. Kaplan, and M. S. Hirsch. 1985. Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate. Lancet i:1480-1482.
28. Studies of Ocular Complications of AIDS Research Group (SOCA) AIDS Clinical Trials Group. 1992. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N. Engl. J. Med. 326:213-220.
29. Tachedjian, G. 1996. Characterisation of foscarnet resistant strains of human immunodeficiency virus type 1. Ph.D. dissertation. Monash University, Melbourne, Australia.
30. Tachedjian, G., D. J. Hooker, A. D. Gurusinghe, H. Bazmi, N. J. Deacon, J. Mellors, C. Birch, and J. Mills. 1995. Characterisation of foscarnet-resistant strains of human immunodeficiency virus type 1. Virology 212:58-68.
31. Tachedjian, G., J. Mellors, H. Bazmi, C. Birch, and J. Mills. 1996. Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet. J. Virol. 70:7171-7181.
32. Tachedjian, G., J. W. Mellors, H. Bazmi, and J. Mills. 1998. Impaired fitness of foscarnet-resistant strains of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 14:1059-1064.
33. Tachedjian, M., J. Krywult, R. J. Moore, and A. L. M. Hodgson. 1995. Caseous lymphadenitis vaccine development: site-specific inactivation of the Corynebacterium pseudotuberculosis phospholipase D gene. Vaccine 13. 1785-1792.